ArticleCell death & disease2020

Preclinical studies using cisplatin/carboplatin to restore the Enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppress Enzalutamide resistant prostate cancer.

Fu-Ju Chou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.